Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Fibrosis and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TIMP1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TIMP1 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View TIMP1 Products |
| Gene Delivery | TIMP1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression assays. |
View TIMP1 Products |
| Benchmark Ab | Anti-TIMP1 Recombinant Antibody Recombinant positive control for binding and neutralization assays. |
View TIMP1 Products |
| Validator | TIMP1 siRNA Set For target knockdown verification in phenotypic and functional assays. |
View TIMP1 Products |
| Related Target A | MMP9 Primary enzymatic partner of TIMP1; crucial for MMP9/TIMP1 complex inhibition assays. |
View MMP9 Products |
| Related Target B | TIMP2 Homologous family member; essential for selectivity and off-target screening. |
View TIMP2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species reactivity validation (Cyno/Mouse) | Human, Mouse, and Cynomolgus TIMP1 ortholog proteins available with >95% purity. |
| Subfamily counter-screening (TIMP1 vs TIMP2/3/4) | Full panel of recombinant TIMP family proteins strictly verified by mass spectrometry and SDS-PAGE. |
| Lack of reliable positive controls | Clinical benchmark antibodies (biosimilars) included to calibrate assay sensitivity. |
| False positives in phenotypic assays | Sequence-verified siRNA included for target-specific knockdown validation. |
Live TIMP1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TIMP1 therapeutics is intensifying, with major players shifting focus from traditional non-selective metalloproteinase modulation to highly targeted biologics. As first-generation therapies reach the clinic, the next wave of R&D is targeting the dual role of TIMP1 in extracellular matrix (ECM) remodeling and CD63-mediated signaling pathways in tumor microenvironments.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Biotech Innovators, Academic Medical Centers | Liver Fibrosis, NASH, Solid Tumors | Blocking Assay (Need high-purity HEK293-expressed TIMP1 to mimic native glycosylation) |
| siRNA / RNAi | RNA Therapeutics Specialists | Idiopathic Pulmonary Fibrosis (IPF) | Knockdown Validation (Need sequence-verified siRNA and qRT-PCR validation controls) |
| Small Molecule Inhibitors | Global Pharmaceutical Corporates | Cancer Metastasis, Fibrotic Diseases | Selectivity Screening (Need TIMP1 vs TIMP2/TIMP3/TIMP4 protein panel) |